Correction (DOI:10.1016/j.cgh.2006.03.002);Serious Infections and Mortality in Association With Therapies for Crohn's Disease: TREAT Registry

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 5, 2006, Pages 621-630

  Lichtenstein, Gary R ^a   Feagan, Brian G ^b   Cohen, Russell D ^c   Salzberg, Bruce A ^d   Diamond, Robert H ^e   Chen, Donny M ^f   Pritchard, Michelle L ^f   Sandborn, William J ^g  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d Atlanta Gastroenterology Associates   (United States)

^e CENTOCOR INC   (United States)

^f Ovation Research Group   (United States)

^g MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646147141     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.05.015     Document Type: Erratum

References (29)

1. Rutgeerts P., van Assche G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
2. Hanauer S.B. Drug therapy. inflammatory bowel disease. N Engl J Med 334 (1996) 841-848
3. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
4. Targan S.R., Hanauer S.B., van Deventer S.J.H., et al., Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
5. Rutgeerts P., Feagan B.F., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
6. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease. the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
7. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
8. Present D.H., Rugeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
9. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
10. Stuck A.E., Minder C., and Frey F.J. Risk of infectious complication in patients taking glucocorticosteroids. Rev Infect Dis 11 (1989) 954-963
11. Yang Y.X., and Lichtenstein G.R. Corticosteroids in Crohn's disease. Am J Gastroenterol 97 (2002) 803-823
12. Sandborn W.J. A review of immune modifier therapy for inflammatory bowel disease. azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 91 (1996) 423-433
13. Aucott J.N. Glucocorticoids and infection. Endocrinol Metab Clin North Am 23 (1994) 655-670
14. Klein N.C., Go C.H., and Cunha B.A. Infections associated with steroid use. Infect Dis Clin North Am 15 (2001) 423-432
15. Colombel J.F., Loftus E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease. the Mayo Clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
16. Ricart E., Panaccione R., Loftus E.V., et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic. the first 100 patients. Am J Gastroenterol 96 (2001) 722-729
17. Cohen R.D., Tsang J.F., and Hanauer S.B. Infliximab in Crohn's disease. first anniversary clinical experience. Am J Gastroenterol 95 (2000) 3469-3477
18. Farrell R.J., Shah S.A., Lodhavia P.J., et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 95 (2000) 3490-3497
19. Hanauer S.B., Sandborn W., and Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 96 (2001) 635-643
20. Hosmer D.W., and Lemeshow S. Applied logistic regression (1998), John Wiley & Sons, Inc, New York
21. Ljung T., Karlén P., Schmidt D., et al. Infliximab in inflammatory bowel disease. clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
22. Jess T., Winther K.V., Munkhol P., et al. Mortality and causes of death in Crohn's disease. follow-up of a population based cohort in Copenhagen, Denmark. Gastroenterology 122 (2002) 1808-1814
23. Loftus E.V., Silverstein M.D., Sandborn W.J., et al. Crohn's disease in Olmstead County, Minnesota, 1940-1993. incidence, prevalence, and survival. Gastroenterology 114 (1998) 1161-1168
24. Farmer R.G., Whelan G., and Fazio V.W. Long-term follow-up of patients with Crohn's disease. Relationship between clinical pattern and prognosis. Gastroenterology 88 (1985) 1818-1825
25. Ekbom A., Helmick C.G., Zack M., et al. Survival and causes of death in patients with inflammatory-bowel disease. a population-based study. Gastroenterology 103 (1992) 954-960
26. Present D.H., Meltzer S.J., Krumholz M.P., et al. 6-mercaptopurine in the management of inflammatory bowel disease. short- and long-term toxicity. Ann Intern Med 111 (1989) 641-649
27. Aberra F.N., Lewis J.D., Hass D., et al. Corticosteroids and immunomodulators. postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125 (2003) 320-327
28. Edwards J.T., Radford-Smith G.L., and Florin T.H. Chronic narcotic use in inflammatory bowel disease patients. prevalence and clinical characteristics. J Gastroenterol Hepatol 16 (2001) 1235-1238
29. Kaplan M.A., and Korelitz B.I. Narcotic dependence in inflammatory bowel disease. J Clin Gastroenterol 10 (1988) 275-278